NEWS | Aug 2, 2021
TBI is a signature wound of recent wars
Award will accelerate development of Sense’s rapid, non-invasive brain scanners through clinical testing, to enable objective method of detecting and continuously monitoring TBI through transport to field hospital
Sense Neuro Diagnostics, a medical technology company focused on improving outcomes for stroke and brain injury patients, today announced its selection by the U.S. Army Medical Research and Development Command (USAMRDC) Combat Casualty Care Research Program to receive $2.43 million from the U.S. Department of Defense to advance technology to diagnose and monitor traumatic brain injury (TBI) in a field environment. The award was issued through Medical Technology Enterprise Consortium (MTEC), a biomedical technology consortium working to advance innovative medical solutions to keep military personnel healthy and fully operational.
“We believe Sense Neuro Diagnostics is well positioned to deliver on USAMRDC’s goals of improving outcomes for service members who suffer traumatic brain injury,” said Geoff Klass, CEO of Sense Neuro Diagnostics. “With rapid detection and continuous monitoring, our technology will enable proper triage and treatment when it matters most.”
Sense is developing rapid, non-invasive brain scanners that use low-power tailored radio frequency (RF) pulse to detect TBI in seconds and, through continuous monitoring, indications of expanding brain hemorrhage. The scanners are small, flexible, and portable, designed to fit on a patient’s head like a cap. The technology was invented by Sense’s medical co-founders who are specialists in emergency medicine, neurology and neurocritical care.
The MTEC award will fund the completion of product development and clinical testing over the next 18 months.
“It’s an honor to develop technology for the USAMRDC that has potential to improve outcomes for the men and women who suffer traumatic injury in service to our country,” said Daniel Kincaid, Chief Operating Officer of Sense Neuro Diagnostics.
About U.S. Army Medical Research and Development Command
The U.S. Army Medical Research and Development Command is the Army’s medical materiel developer, with responsibility for medical research, development, and acquisition. USAMRDC produces medical solutions for the battlefield with a focus on various areas of biomedical research, including military infectious diseases, combat casualty care, military operational medicine, medical chemical and biological defense. https://mrdc.amedd.army.mil/
The Neurotrauma and Traumatic Brain Injury Portfolio is a requirements-based program that seeks to improve the far-forward capabilities of military diagnostic and treatment for the spectrum of TBI severities, with emphasis on moderate and severe TBI and polytrauma under Multi-Domain Operations in prolonged field care scenarios. https://ccc.amedd.army.mil/Portfolios/Pages/NTBI.aspx
MTEC is a biomedical technology consortium collaborating with multiple government agencies under a 10-year renewable Other Transactional Agreement with the U.S. Army Medical Research and Development Command. To find out more about MTEC, visit mtec-sc.org.
Sense Neuro Diagnostics is a medical technology company focused on improving outcomes for stroke and brain injury patients through technology innovations that enable faster detection and more effective triage. Sense is developing non-invasive technology to enable continuous, real-time brain injury monitoring as well as rapid detection of traumatic brain injury and important stroke subtypes—ischemic stroke with large vessel occlusion, ischemic stroke without large vessel occlusion, and intracerebral hemorrhage. Learn about the ongoing pivotal trial for continuous monitoring of intracranial hemorrhage, and successful first-in-human pilot study of triage technology to determine stroke subtype at https://senseneuro.com or find Sense Neuro Diagnostics on LinkedIn or Twitter @SenseDx.